乳腺癌术后上肢淋巴水肿的研究进展

doi:10.3969/j.issn.1004-616x.2025.03.014

[1] 刘兆喆, 李秋华, 李文雅, 等. 乳腺癌术后淋巴水肿中西医结合诊治中国专家共识[J]. 创伤与急危重病医学, 2023, 11(1): 1-8.
[2] GÄRTNER R, MEJDAHL M K, ANDERSEN K G, et al. Development in self-reported arm-lymphedema in Danish women treated for early-stage breast cancer in 2005 and 2006: a nationwide follow-up study[J]. Breast, 2014, 23(4): 445-452.
[3] KIBAR S, DALYAN ARAS M, ÜNSAL DELIALIOĞLU S. The risk factors and prevalence of upper extremity impairments and an analysis of effects of lymphoedema and other impairments on the quality of life of breast cancer patients[J]. Eur J Cancer Care, 2017, 26(4). DOI: 10.1111/ ecc.12433.
[4] WETZIG N, GILL P G, ZANNINO D, et al. Sentinel lymph node based management or routine axillary clearance? Three-year outcomes of the RACS sentinel node biopsy versus axillary clearance (SNAC) 1 trial[J]. Ann Surg Oncol, 2015, 22(1): 17-23.
[5] FU M R. Breast cancer-related lymphedema: symptoms, diagnosis, risk reduction, and management[J]. World J Clin Oncol, 2014, 5(3): 241- 247.
[6] RUPP J, HADAMITZKY C, HENKENBERENS C, et al. Frequency and risk factors for arm lymphedema after multimodal breast-conserving treatment of nodal positive breast Cancer - a long-term observation[J]. Radiat Oncol, 2019, 14(1): 39.
[7] 李喆, 葛海燕. 乳腺癌根治术后上肢淋巴水肿的研究进展[J]. 中华乳腺病杂志: 电子版, 2012, 6(2): 201-208.
[8] STANTON A W B, MODI S, BENNETT BRITTON T M, et al. Lymphatic drainage in the muscle and subcutis of the arm after breast cancer treatment[J]. Breast Cancer Res Treat, 2009, 117(3): 549-557.
[9] BATES D O. The chronic effect of vascular endothelial growth factor on individually perfused frog mesenteric microvessels[J]. J Physiol, 1998, 513(Sup 1): 225-233.
[10] ZAMPELL J C, YAN A L, ELHADAD S, et al. CD4⁺ cells regulate fibrosis and lymphangiogenesis in response to lymphatic fluid stasis[J]. PLoS One, 2012, 7(11): e49940.
[11] AVRAHAM T, ZAMPELL J C, YAN A L, et al. Th2 differentiation is necessary for soft tissue fibrosis and lymphatic dysfunction resulting from lymphedema[J]. FASEB J, 2013, 27(3): 1114-1126.
[12] VON DER WEID P Y, RAHMAN M, IMTIAZ M S, et al. Spontaneous transient depolarizations in lymphatic vessels of the guinea pig mesentery: pharmacology and implication for spontaneous contractility [J]. Am J Physiol Heart Circ Physiol, 2008, 295(5): H1989-H2000.
[13] SENATORE A, GUAN W, SPAFFORD J D. Cav3 T-type channels: regulators for gating, membrane expression, and cation selectivity[J]. Pflugers Arch, 2014, 466(4): 645-660.
[14] DISIPIO T, RYE S, NEWMAN B, et al. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis [J]. Lancet Oncol, 2013, 14(6): 500-515.
[15] HINRICHS C S, WATROBA N L, REZAISHIRAZ H, et al. Lymphedema secondary to postmastectomy radiation: incidence and risk factors[J]. Ann Surg Oncol, 2004, 11(6): 573-580.
[16] NORMAN S A, LOCALIO A R, KALLAN M J, et al. Risk factors for lymphedema after breast cancer treatment[J]. Cancer Epidemiol Biomark Prev, 2010, 19(11): 2734-2746.
[17] VETTO J T. Lymphedema after breast cancer treatment-not just the surgeon’s fault[J]. JAMA Surg, 2019, 154(9): 810.
[18] FERGUSON C M, SWAROOP M N, HORICK N, et al. Impact of ipsilateral blood draws, injections, blood pressure measurements, and air travel on the risk of lymphedema for patients treated for breast cancer [J]. J Clin Oncol, 2016, 34(7): 691-698.
[19] HASENOEHRL T, PALMA S, RAMAZANOVA D, et al. Resistance exercise and breast cancer-related lymphedema-a systematic review update and meta-analysis[J]. Support Care Cancer, 2020, 28(8): 3593- 3603.
[20] ABDELHAMID M I, BARI A A, FARID M I, et al. Evaluation of axillary reverse mapping (ARM) in clinically axillary node negative breast cancer patients-Randomised controlled trial[J]. Int J Surg, 2020, 75: 174-178.
[21] PASKO J L, GARREAU J, CARL A, et al. Axillary reverse lymphatic mapping reduces patient perceived incidence of lymphedema after axillary dissection in breast cancer[J]. Am J Surg, 2015, 209(5): 890-895.
[22] YUAN Q Q, WU G S, XIAO S Y, et al. Identification and preservation of arm lymphatic system in axillary dissection for breast cancer to reduce arm lymphedema events: a randomized clinical trial[J]. Ann Surg Oncol, 2019, 26(11): 3446-3454.
[23] BOCCARDO F M, CASABONA F, FRIEDMAN D, et al. Surgical prevention of arm lymphedema after breast cancer treatment[J]. Ann Surg Oncol, 2011, 18(9): 2500-2505.
[24] BOZKURT M, PALMER L J, GUO Y. Effectiveness of decongestive lymphatic therapy in patients with lymphedema resulting from breast cancer treatment regardless of previous lymphedema treatment[J]. Breast J, 2017, 23(2): 154-158.
[25] BAXTER G D, LIU L Z, TUMILTY S, et al. Low level laser therapy for the management of breast cancer-related lymphedema: a randomized controlled feasibility study[J]. Lasers Surg Med, 2018, 50(9): 924-932.
[26] SZUBA A, ACHALU R, ROCKSON S G. Decongestive lymphatic therapy for patients with breast carcinoma-associated lymphedema. A randomized, prospective study of a role for adjunctive intermittent pneumatic compression[J]. Cancer, 2002, 95(11): 2260-2267.
[27] 霍永平, 阎丽婷, 夏利敏, 等. 地奥司明联合负压淋巴回流治疗乳腺癌术后上肢淋巴水肿疗效分析[J]. 中国现代普通外科进展, 2021, 24(4): 296-298.
[28] 齐雪, 杨秀, 关红丹. 地奥司明联合己酮可可碱治疗乳腺癌术后患侧上肢淋巴水肿的临床效果[J]. 临床合理用药, 2024, 17(18): 136-138.
[29] 胡书源, 柳弥. 乳腺癌上肢淋巴水肿的研究进展[J]. 肿瘤预防与治疗, 2021, 34(3): 262-268.
[30] 郝昆, 孙宇光, 王仁贵, 等. 抽吸减容术治疗乳腺癌术后上肢淋巴水肿[J]. 组织工程与重建外科, 2024, 20(1): 69-74, 82.
[31] DAMSTRA R J, VOESTEN H M, KLINKERT P, et al. Circumferential suction-assisted lipectomy for lymphoedema after surgery for breast cancer[J]. Br J Surg, 2009, 96(8): 859-864.
[32] PHILLIPS G S A, GORE S, RAMSDEN A, et al. Lymphaticovenular anastomosis improves quality of life and limb volume in patients with secondary lymphedema after breast cancer treatment[J]. Breast J, 2019, 25(5): 859-864.
[33] 中华医学会整形外科学分会淋巴水肿治疗学组. 乳腺癌术后上肢淋巴水肿诊治指南与规范(2021年版)[J]. 组织工程与重建外科, 2021, 17(6): 457-461.
[34] SCHAVERIEN M V, BADASH I, PATEL K M, et al. Vascularized lymph node transfer for lymphedema[J]. Semin Plast Surg, 2018, 32(1): 28-35.
[35] MOUSAVI S R, AKBARI M E, ZARRINTAN S. Vascularized gastroepiploic lymph node transfer significantly improves breast cancer-related lymphedema[J]. J Surg Oncol, 2020, 121(1): 163-167.
[36] FORTE A J, HUAYLLANI M T, BOCZAR D, et al. Lipoaspiration and lymph node transfer for treatment of breast cancer-related lymphedema: a systematic review[J]. Cureus, 2019, 11(11): e6096.
[37] LEPPÄPUSKA I M, SUOMINEN E, VIITANEN T, et al. Combined surgical treatment for chronic upper extremity lymphedema patients: simultaneous lymph node transfer and liposuction[J]. Ann Plast Surg, 2019, 83(3): 308-317.
[38] ZHOU H, WANG M, HOU C Q, et al. Exogenous VEGF-C augments the efficacy of therapeutic lymphangiogenesis induced by allogenic bone marrow stromal cells in a rabbit model of limb secondary lymphedema [J]. Jpn J Clin Oncol, 2011, 41(7): 841-846.
[39] MALDONADO G E M, PÉREZ C A A, COVARRUBIAS E E A, et al. Autologous stem cells for the treatment of post-mastectomy lymphedema: a pilot study[J]. Cytotherapy, 2011, 13(10): 1249-1255.

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Lü Jie, CHEN Zhonghua, WANG Bo. The role of circular RNA homeodomain interacting protein kinase 3 in triple-negative breast cancer cell invasion [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2025, 37(1): 39-44,51.
[2]	YANG Yihui, ZHANG Wenxia, GONG Zhining, CEN Xuexue, QIN Qimin, TANG Hongping. Clinicopathological characterization of HER-2-low cases among breast cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(6): 457-462.
[3]	SHU Xingmei, SHI Xiaoqian, LIU Yan, LI Dan. Expression of ribosomal protein S6K1 and its regulation on malignant phenotypes in breast cancer cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(3): 179-186,223.
[4]	ZHANG Haizhi, WEN Xiaofen, HUANG Binliang, LIN Hui, XUE Wenwu, ZENG De, LIN Danxia. Expression and clinical significance of SLC50A1 in breast carcinomas [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(5): 373-377.
[5]	WANG Xujuan, LUO Yongxin, LI Chenqiang, WANG Rujin, ZHENG Tingting. Predictive values of preoperative laboratory indices dNLR, SII and CRP/ALB on recurrences and metastases in breast cancer patient [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(4): 284-288,323.
[6]	ZHANG Yue, WANG Yaoyi, WU Xueliang, ZHANG Zhisheng, YANG Xiuming, JIANG Yang, QIAO Zhifei, LIANG Wanping, XUE Jun. The combination of ¹²⁵I particles and AZD1152 efficiently inhibited proliferation and promoted apoptosis of a triple negative breast cancer cell line [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(4): 295-299,306.
[7]	FAN Xiaojie, LI Qingjing, GU Lina, SANG Meixiang, SHAN Baoen. Expression of melanoma-associated antigen A gene family in breast cancer and its clinical significance [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(3): 184-191.
[8]	GUO Xiaojuan, WANG Jinxi, NIU Guangxu, TIAN Yunxiao. Expression and correlation analyses of EGFR and HER-2 in different types of breast cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(2): 119-123,148.
[9]	FANG Yutong, ZHANG Qunchen, HONG Chaoqun, CHEN Chunfa, CHEN Jiongyu, ZHANG Rendong, WU Jundong. Mechanisms of miR-221 and miR-222 on expression of GATA3 and FOXA1 and their effects in breast cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 0, (): 435-441,460.
[10]	CHENG Bin, WANG Xinyu, SUN Yu, ZHANG Jiatai, DONG Shuying. Inhibition of metformin on phthalate-induced proliferation and migration of MCF-7 breast cancer cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 197-202.
[11]	LUO Jiao, ZHANG Kunchi, ZHOU Li. Analysis of differentially expressed microRNAs between the triple negative breast cancer cell line MDA-MB-231 and its brain metastasis cell line [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 218-224.
[12]	ZHANG Yuling, WU Jundong, PANG Dongyue, CHEN Chunfa. Changes of Ki67 expression before and after neoadjuvant chemotherapy as a predictor for therapeutic response and rognosis in breast cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 230-235,245.
[13]	LI Weiwei, ZHU Ying. Data mining analyses of expression and prognostic values of the MYB family in breast cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 414-422.
[14]	ZHANG Huijuan, HUANG Dayuan, ZHANG Jie, TANG Haiou, XIE Anxin, TAN Dunyong. Effects of SF1a-PRLR and ΔS2 SF1a-PRLR on proliferation and microRNA expressionin MCF-7 breast cancer cell [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(3): 203-208.
[15]	SUN Quanwu, DU Xiaoping, HAO Jie, SHI Rong, LIU Bo, HUANG Haiyun. β1 integrin expression in breast cancer patients with pathological nipple discharge [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(5): 368-372.